{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:56:49Z","timestamp":1760241409643,"version":"build-2065373602"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The emerging combination of radiation therapy with vaccines is a promising new treatment plan in the fight against cancer. While many cancer vaccines such as MUC1, p53 CpG oligodeoxynucleotide, and SOX2 may be great candidates for antitumor vaccination, there still remain many investigations to be done into possible vaccine combinations. One fruitful partnership that has emerged are anti-tumor vaccines in combination with radiation. Radiation therapy was previously thought to be only a tool for directly or indirectly damaging DNA and therefore causing cancer cell death. Now, with much preclinical and clinical data, radiation has taken on the role of an in situ vaccine. With both cancer vaccines and radiation at our disposal, more and more studies are looking to combining vaccine types such as toll-like receptors, viral components, dendritic-cell-based, and subunit vaccines with radiation. While the outcomes of these combinatory efforts are promising, there is still much work to be covered. This review sheds light on the current state of affairs in cancer vaccines and how radiation will bring its story into the future.<\/jats:p>","DOI":"10.3390\/vaccines6010009","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T05:02:34Z","timestamp":1517288554000},"page":"9","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Radiation and Anti-Cancer Vaccines: A Winning Combination"],"prefix":"10.3390","volume":"6","author":[{"given":"Alexandra","family":"Cadena","sequence":"first","affiliation":[{"name":"Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-5537","authenticated-orcid":false,"given":"Taylor","family":"Cushman","sequence":"additional","affiliation":[{"name":"Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark","family":"Anderson","sequence":"additional","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79415, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hampartsoum","family":"Barsoumian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Welsh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cortez","sequence":"additional","affiliation":[{"name":"Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-t immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1517\/14712598.2011.598146","article-title":"Muc1 peptide vaccine mediated antitumor activity in non-small cell lung cancer","volume":"11","author":"Sharma","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"Muc1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory t cells and natural killer t cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1200\/JCO.2005.13.011","article-title":"Randomized Phase iib trial of blp25 liposome vaccine in stage iiib and iv non-small-cell lung cancer","volume":"23","author":"Butts","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","first-page":"1603","article-title":"Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung cancer study group","volume":"5","author":"Chiba","year":"1990","journal-title":"Oncogene"},{"key":"ref_9","first-page":"171","article-title":"P53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features","volume":"7","author":"Mitsudomi","year":"1992","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"Ingn-225: A dendritic-cell-based p53 vaccine (ad.P53-dc) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ijc.25980","article-title":"Long-term clinical and immunological effects of p53-slp(r) vaccine in patients with ovarian cancer","volume":"130","author":"Leffers","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-13-2617","article-title":"Phase i dendritic cell p53 peptide vaccine for head and neck cancer","volume":"20","author":"Schuler","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3892\/ijo.2014.2402","article-title":"Antitumor DNA vaccination against the sox2 transcription factor","volume":"45","author":"Polakova","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1073\/pnas.97.8.4198","article-title":"Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer","volume":"97","author":"Gure","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem-cell-associated antigen sox2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e25205","DOI":"10.4161\/onci.25205","article-title":"Sox2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer","volume":"2","author":"Dhodapkar","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","article-title":"Abscopal effects of radiation therapy: A clinical review for the radiobiologist","volume":"356","author":"Siva","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_19","first-page":"1229","article-title":"Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma","volume":"63","author":"Stone","year":"1979","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","article-title":"Radiation therapy to convert the tumor into an in situ vaccine","volume":"84","author":"Formenti","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/imt.15.65","article-title":"Strategies for combining immunotherapy with radiation for anticancer therapy","volume":"7","author":"Seyedin","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","article-title":"Combining radiation and immunotherapy: A new systemic therapy for solid tumors?","volume":"2","author":"Tang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of b16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","article-title":"Suppression of type i ifn signaling in tumors mediates resistance to anti-pd-1 treatment that can be overcome by radiotherapy","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","article-title":"Tgfbeta is a master regulator of radiation therapy-induced antitumor immunity","volume":"75","author":"Diamond","year":"2015","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K.A., Garcia-Martinez, E., Rudqvist, N.P., Formenti, S.C., and Demaria, S. (2017). Barriers to radiation-induced in situ tumor vaccination. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00229"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/imr.12572","article-title":"Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases","volume":"280","author":"Frey","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000437185","article-title":"Radiotherapy and immunotherapy: Improving cancer treatment through synergy","volume":"42","author":"Reynders","year":"2015","journal-title":"Prog. Tumor Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","article-title":"Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma","volume":"4","author":"Theurich","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1593\/tlo.12280","article-title":"A systemic complete response of metastatic melanoma to local radiation and immunotherapy","volume":"5","author":"Hiniker","year":"2012","journal-title":"Transl. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2012-05-432393","article-title":"Systemic delivery of a tlr7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma","volume":"121","author":"Dovedi","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","article-title":"Topical tlr7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer","volume":"18","author":"Adams","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00411-006-0076-x","article-title":"Ionizing radiation stimulates secretion of pro-inflammatory cytokines: Dose-response relationship, mechanisms and implications","volume":"46","author":"Shan","year":"2007","journal-title":"Radiat. Environ. Biophys."},{"key":"ref_37","first-page":"5429","article-title":"Oligodeoxynucleotides containing cpg motifs can induce rejection of a neuroblastoma in mice","volume":"59","author":"Carpentier","year":"1999","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11912-004-0019-0","article-title":"Antitumor applications of stimulating toll-like receptor 9 with cpg oligodeoxynucleotides","volume":"6","author":"Krieg","year":"2004","journal-title":"Curr. Oncol. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/nop047","article-title":"Intracerebral administration of cpg oligonucleotide for patients with recurrent glioblastoma: A Phase ii study","volume":"12","author":"Carpentier","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_40","first-page":"2263","article-title":"Phase i trial of wilms\u2019 tumor 1 (wt1) peptide vaccine with gm-csf or cpg in patients with solid malignancy","volume":"32","author":"Ohno","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1215\/S1522851705000475","article-title":"Phase 1 trial of a cpg oligodeoxynucleotide for patients with recurrent glioblastoma","volume":"8","author":"Carpentier","year":"2006","journal-title":"Neuro-Oncology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-07-0050","article-title":"Intradermal cpg-b activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients","volume":"13","author":"Molenkamp","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a tlr9 agonist combined with radiation: A Phase 1\/2 study","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-04-0073","article-title":"External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated t-cell killing","volume":"64","author":"Chakraborty","year":"2004","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-008-0449-x","article-title":"Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects","volume":"57","author":"Chakraborty","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1078-0432.CCR-07-5162","article-title":"Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant","volume":"14","author":"Lechleider","year":"2008","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/pcan.2012.7","article-title":"Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy","volume":"15","author":"Kamrava","year":"2012","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/1535-7163.MCT-14-1015","article-title":"Synergy of radiotherapy and a cancer vaccine for the treatment of hpv-associated head and neck cancer","volume":"14","author":"Mondini","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/sj.mt.6300149","article-title":"Increased sensitivity of radiated murine cervical cancer tumors to e7 subunit vaccine-driven ctl-mediated killing induces synergistic anti-tumor activity","volume":"15","author":"Ye","year":"2007","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon.09.46","article-title":"Vitespen: A preclinical and clinical review","volume":"5","author":"Wood","year":"2009","journal-title":"Future Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Eton, O., Ross, M.I., East, M.J., Mansfield, P.F., Papadopoulos, N., Ellerhorst, J.A., Bedikian, A.Y., and Lee, J.E. (2010). Autologous tumor-derived heat-shock protein peptide complex-96 (hsppc-96) in patients with metastatic melanoma. J. Transl. Med., 8.","DOI":"10.1186\/1479-5876-8-9"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:53:00Z","timestamp":1760194380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["vaccines6010009"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6010009","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}